On Tuesday, Trevi Therapeutics Inc (NASDAQ: TRVI) opened higher 2.64% from the last session, before settling in for the closing price of $6.82. Price fluctuations for TRVI have ranged from $2.36 to $7.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 27.09% annually for the last half of the decade. Company’s average yearly earnings per share was noted 8.52% at the time writing. With a float of $69.87 million, this company’s outstanding shares have now reached $99.89 million.
In an organization with 26 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 47.38%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.29% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Check out the current performance indicators for Trevi Therapeutics Inc (TRVI). In the past quarter, the stock posted a quick ratio of 15.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.86 million. That was better than the volume of 1.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.22%.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 85.50%, which indicates a significant decrease from 88.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.36 in the past 14 days, which was lower than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.29, while its 200-day Moving Average is $4.85. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $7.12. Second resistance stands at $7.24. The third major resistance level sits at $7.46. If the price goes on to break the first support level at $6.78, it is likely to go to the next support level at $6.55. Assuming the price breaks the second support level, the third support level stands at $6.43.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
There are currently 117,293K shares outstanding in the company with a market cap of 834.02 million. Presently, the company’s annual sales total 0 K according to its annual income of -47,910 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,340 K.
